Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

Longer survival was seen in those with melanoma who received programmed cell death receptor-1 or its ligand who had a low neutrophil-lymphocyte ratio.

The study is looking at the combination of BNT111 with Regeneron's PD-1 inhibitor Libtayo (cemiplimab) in 184 patients with advanced melanoma who have relapsed after or not responded to treatment ...

"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...

An expert explained how a patient’s own T cells can be extracted, manufactured and infused back into the body as a treatment ...

We recently presented encouraging efficacy and safety data at ESMO on NUC-7738 plus pembrolizumab in patients with metastatic melanoma who were refractory or resistant to PD-1 inhibitors. We are ...

The majority of patients had received prior PD-(L)1 based therapy. Encouraging signals of anti-cancer activity were observed ... 75-year-old patient with BRAF mutant metastatic cutaneous melanoma who ...

Like PD-1, LAG-3 is a negative regulator of T cells ... the phase 2/3 RELATIVITY-047 trial in unresectable or metastatic melanoma, which demonstrated that patients on the combination drug had ...

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

Vidutolimod and nivolumab demonstrated activity in a phase 2 trial of patients with high-risk, resectable melanoma.

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...